Latest Members

Medicon Valley Alliance is continually adding new life science companies and organisations as members.

These companies and organisations have decided to join forces and strengthen their ties within the region, thereby anhancing their visibility with national and international companies looking at life science in Medicon Valley.

Below is a list of the companies that have most recently joined the Medicon Valley Alliance!

Take a look and see if one of them is your new business partner. If you wish to view a directory of all companies and organisations in Medicon Valley – click here!


Covington is a pre-eminent international law firm with more than 1,300 lawyers and advisors and 13 offices around the globe in Europe, the United States, the United Kingdom, Asia, the Middle East, and South Africa. We are known for the high quality of our work, in-depth knowledge of key industries, sophistication in complex corporate, regulatory, advisory, and contentious matters, deep loyalty to clients, and commitment to the highest professional and ethical standards.

We offer one of the largest and most comprehensive life sciences industry practices in the world encompassing the full range of pharmaceutical, biotechnology, medical device, digital health, veterinary, food and beverage, dietary supplement, and cosmetics issues. Through our offices in Europe, the United States, the United Kingdom, and China and a network of local counsel, we advise emerging companies, multinational corporations, and trade associations on a global basis. They know that they can rely on Covington for practical, efficient solutions rooted in a sophisticated knowledge of their business that only comes from deep immersion in the industry and decades of dedicated service. We are the only firm ranked “Band 1” for Life Sciences across Chambers’ Europe, US, UK, China, and Global surveys.

Find out more at

4C Life Sciences

For patients, and in turn sponsors and service providers, speed and efficacy are fundamental.  Both of these outcomes are underpinned by careful value chain configuration.  This requires decisions to determine where competitive advantages lie, weighing make vs. buy options, and then selecting the right capabilities, partners and technologies to execute. Execution that requires coordination, collaboration and shared objectives across networks and ecosystems. 4C Life Sciences brings deep experience to these value chain configuration decisions – defining strategy, implementing new solutions, and ultimately supporting operational delivery of outcomes and realization of value.

4C Life Sciences are value chain configuration experts for our industry, offering a diverse set of services across the biopharma value chain.  We are a passionate group of practitioners, combining deep life sciences industry expertise with deep advisory and delivery experience.

We have a focused market offering and deliver three core offerings to our biopharma clients:

  • Enterprise Strategy & Operations – Partnering with C-Suite executives to transform their organization from an enterprise level to a functional level by helping them define & implement their strategy and enabling operating model.
  • Procurement Transformation – Partnering with CPOs and procurement leaders on transformative initiatives to optimize the procurement function and help them deliver a better service to the business.
  • Outsourcing Advisory – An innovative advisory offering, partnering with commercial and operational leaders on the optimal way to use the external market to deliver their R&D portfolio and maximize returns.

Our clients are at all stages of growth, from start-up to global mega-pharma, and include leading multi-national research, pharmaceutical, diagnostic, instrumentation, med-tech and biotech innovators.


Founded in Europe, NUVISAN is a fully integrated Contract Research Organization with a 40-year track record of serving clients’ needs in early and clinical development for pharmaceutical and biotech companies.

The company’s fully integrated value chain of GxP solutions from early research to phase II clinical trials enhances efficiency, compliance and data quality to safely and effectively support your products to the market.

With more than 1000 employees located in six research sites in Europe (Germany and France) and with local experts situated in Latin America, NUVISAN is pleased to offer the following portfolio of services:

• Drug discovery & research
• Non-clinical studies
• Pharmaceutical analysis
• Topical formulation development
• Chemical development with GMP manufacturing (3-10kg)
• Bioanalytical labs
• GMP manufacturing (up to 50 Kg)
• Clinical trial supplies
• Phase 1 and 2 clinical studies

Our services are provided as stand-alone or integrated solutions and customized to your project needs.


Founded in 2005, Porton is a leading pharmaceutical CDMO in China. From the early stage of drug development, Porton has provided global pharmaceutical companies with customized R&D. With over 4500 customer-centric employees, operations and commercial offices across the US, EU and China, Porton Pharma Solutions provides global pharmaceutical companies with innovative, reliable and end-to-end process R&D and manufacturing services across small molecule APIs, dosage forms and biologics.

Our Process Technology Centers and WHO/USFDA/EMA/PDMA/NMPA-inspected Manufacturing Facilities feature state-of-the-art equipment, highly flexible cGMP-compliant production assets, plus over 1200 highly skilled scientists and process engineers, all backed by a proven program management system dedicated to seamlessly delivering successful outcomes for your unique project requirements.

We are committed to be the most open, innovative and reliable pharmaceutical service platform in the world and Enabling public’s early access to good medicines. We constantly strive for excellence, and have been recognized through awards by industry forums and global pharmaceutical companies for our process innovation, supply chain performance and compliance with global Quality and EHS standards. By efficiently advancing development and enabling commercialization of multiple high-impact medicines, Porton is proud to have earned the trust of some of the world’s leading and most innovative pharmaceutical companies and many biotechnology companies across the US, EU and Asia.

Eagle Genomics

Eagle Genomics is a software business that is pioneering the application of network science to biology across the Food and Nutrition, Beauty and Personal Care, AgBio and Healthcare sectors. Its purpose is to accelerate the generative economy through the digital reinvention of science. Eagle Genomics’ AI-augmented knowledge discovery platform, e[datascientist] ™, empowers scientists to exploit multi-dimensional data in minutes rather than months, helping companies conduct science-led innovation for next-generation products.

e[datascientist] supports the entire innovation workflow – from hypothesis through insight to product claims – helping bring novel, safer and sustainable products to market. A Cambridge, UK-headquartered business with a global presence, Eagle Genomics has sites in London’s Knowledge Quarter, Hyderabad, India, New York’s Genome Center as well as Paris’ Station F, Potsdam Science Park, Germany and Kyiv, Ukraine.

Find out more at

Ampa Medical

People living with an ileostomy have a significantly decreased quality of life. Living with an ileostomy and wearing an ostomy pouch is often associated with complications such as peristomal skin ulceration, leakage, odor, clothing incompatibilities, physical limitations due to the ostomy pouch and psychological effects of not being able to control the emptying of bowels and living with a changed body image.

In Ampa Medical, we have developed an alternative solution to the ostomy bag to provide users with a normalized life while having an ileostomy. We expect to give users full or partly freedom from the ostomy bag and avoid the potential associated physical and mental problems.

Ampa medical is founded by two clinicians, a medical doctor and a nurse. Meeting people who are challenged by living with an ileostomy, combined with an entrepreneurial mindset has given us a vision to change the lives of people living with ileostomies for the better.


MATOMIC, a Novo Nordisk Foundation 2021 Challenge Programme under Mathematical Modelling of Health and Disease, aims to tackle aspects of the Obesity pandemic.

The obesity pandemic and its comorbidities like diabetes causes very high societal and economic costs and still there are only limited options for treatment. The discovery that the intestinal microbiome is altered in obese patients and the transferability of a metabolic phenotype by fecal microbiome transplantation (FMT) leads the path to a reversal from an obese to a lean phenotype by FMT. All previous attempts of FMT are hampered by often-occurring incompatibilities of the microbiomes from donor and recipient, having a detrimental effect on the stability of the microbiome.

Approaches based on metagenome analysis are falling short of reliability because the metabolic interaction within the microbiota is key for the understanding of the stability of the entire consortium. This in turn is decisive for which microbiome phenotype is dominating the effect on the host. While therapeutic microbial communities show huge potential for a basis of new living treatments, mathematical modelling of functionality and stability of intestinal microbial communities is basically lacking.

MATOMIC aims to use a variety of mathematical modelling approaches, chosen for their potential of automated coarse graining between different levels of abstraction and predictive power with respect to wet-lab experiments. Modelling compounds and reactions on atomic details using graph transformations is essential for the design and interpretation of isotope labelling experiments, and enables a direct verification of compound fluxes using mass spectrometry. Consequently we will combine such metabolic modelling techniques with experimental cultivation of microbiomes of varying complexity for the successful design of stable microbial communities for therapeutic use.

MATOMIC is funded by the Novo Nordisk Foundation, supported by grant NNF21OC0066551.

The University of Southern Denmark welcomed the first students onto the campus in Odense in September 1966, and things have been developing by leaps and bounds ever since. We now have five faculties with more than 27,000 students, almost 20% of whom are from abroad, and more than 3,800 employees distributed across our main campus in Odense and regional campuses in Slagelse, Kolding, Esbjerg and Sønderborg. Several international studies document that we conduct world-class research and are one of the top fifty young universities in the world.

Over the years, the University of Southern Denmark has interwoven many lives. The roughly five years which a student invests in a university education will lay the groundwork for the rest of his or her life. And with around 115 different study programmes in the fields of the humanities, social sciences, natural sciences, health sciences and engineering, graduates of the University of Southern Denmark are now members of virtually every profession in the international community.


We are committed to improving human health with our expertise in data science.

In the forms of collaborations and partnerships, with our advanced knowledges and skills in computations, we are confident that we can accelerate discoveries and innovations in biotech and pharmaceutical companies.


Iconovo brings inhalation expertise to pharmaceutical companies.

Development of inhalation devices requires both a device technology platform and formulation expertise which Iconovo offers for a a global market, both for novel and generic pharmaceuticals. The time the engineers and pharmaceutical experts already have invested in the inhaler platforms at Iconovo, reduces development risk and shortens time to market. There are four dry powder inhaler solutions based on four proprietary differentiated technical platforms from which pharmaceutical companies develop unique inhaler products in close collaboration with Iconovo. Iconovo has significant experience and expertise in developing inhaler products together with pharmaceutical companies. International generic drug companies and pharmaceutical companies that lack the expertise, resources and/or time to develop inhaled products themselves collaborate with Iconovo.

The platforms are :
ICOres – Flexible multi-dose dry powder inhaler with feedback features
ICOcap – Uniquely designed capsule based dry powder inhaler, available from Stevanato
ICOpre – Pre-metered dry powder inhaler for simple, once-daily treatment
ICOone and ICOone Nasal: Single-dose disposable dry powder inhaler for discreet use, with an adaption for nasal inhalation

Iconovo is based in Lund, Sweden.


Optimapharm is a mid-size full-service pan-european CRO that has over 25 offices throughout Europe and is now a local Nordic CRO with the addition of Crown CRO joining the Optimapharm family in 2021. Crown has operated in the Nordics since 2005 and this acquisition further strengthens access for Nordic pharma, biotech and medtech companies to utilize Optimapharms unrivaled access to patients in the Baltics and eastern Europe.

Faster start up times, high quality data and cost effective solutions has resulted in achieving 95% repeat business in supporting our clients for Phase I-IV, MDR, IVDR studies. We provide a high level of expertise within oncology, cns, psychiatry, endocrinology, pulmonology, cardiovascular, rheumatology and vaccines to name a few.

Optimapharm provides a high level of expertise in developing and managing trials combined with a flexible tailor made and collaborative approach across Europe (and the US with our partners).

Here are a few of Optimapharm’s full, individual and out-source services that we offer across the Nordics and Europe:
– Clinical project management
– Regulatory Affairs
– Monitoring
– Feasibility
– Biometrics, Data management and biostatistics
– Quality Affairs, Safety and PV
– Medical Affairs & medical writing
– Short-term and Long-term insourcing